Sumanta Kumar Pal MDClinical Professor, Department of Medical Oncology & Therapeutics Research; Co-Director, Kidney Cancer Program, City of Hope, Duarte, California
Dr. Sumanta (Monty) Pal is a medical oncologist and an internationally recognized leader in the area of genitourinary cancers. He is a Clinical Professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California, where he is co-director of the kidney cancer program and heads up the kidney and bladder cancer disease team at that institution. Dr. Pal entered medical school at the age of 17, and received his MD from the UCLA School of Medicine, where he developed his interest in cancer research. After residency training in internal medicine at the UCLA Medical Center in Los Angeles, he completed a fellowship in medical oncology at City of Hope Comprehensive Cancer Center, where he has remained on faculty since 2009.
Over that time, he has published more than 400 PubMed-cited articles, which have been featured in prominent journals, including The Lancet, Nature Medicine, Cancer Discovery, Journal of Clinical Oncology, The Lancet Oncology, and European Urology, and has presented his work at numerous international meetings. His goal is to translate laboratory discoveries as quickly and efficiently as possible into tangible benefits for patients. Dr. Pal is the lead investigator on multiple trials, ranging from early phase I experiences to late phase III studies. He has received grants from the National Institute of Health, the Comprehensive Cancer Network, SWOG Cancer Research Network, and multiple other leading entities in support of his research.
Clinical Professor, Department of Medical Oncology & Therapeutics Research; Co-Director, Kidney Cancer Program, City of Hope, Duarte, California
MD: UCLA School of Medicine, Los Angeles, California
Fellowship (hematology/oncology): City of Hope/Harbor-UCLA Medical Center, Los Angeles, California
Research Interests:Genitourinary cancers; translational science; microbiome
Sumanta Kumar Pal, MD serves as a consultant to Roche. He also receives institutional research funds from Roche, Genentech, Exelixis, Eisai, and Pfizer.
Recent Contributions to PracticeUpdate:
- Genomic Correlates of Response to Immune Checkpoint Therapies in ccRCC
- Survival After Cytoreductive Nephrectomy in Metastatic Non–Clear Cell Renal Cell Carcinoma
- Renal Cell Carcinoma: Non-Clear Cell RCC—Part 3
- Antibiotics in Kidney Cancer: Preliminary Data From ASCO GU 2018
- Renal Cell Carcinoma: Frontline Treatment—Part 2
- Implications of Data on Cabozantinib vs Nivolumab for mRCC From ASCO GU 2018
- ASCO GU 2018: Analyzing IMmotion151 Data in Light of Results From Checkmate 214 and CABOSUN Trials
- Adjuvant Treatment of RCC—Part 1
- Crizotinib Achieves Long-Lasting Disease Control in Advanced Papillary RCC Type 1 With MET Mutations or Amplification
- Mortality Similar for Prostatectomy and Observation for Early Prostate Cancer